Based on the Blueprint Medicines Corp stock forecast from 9 analysts, the average analyst target price for Blueprint Medicines Corp is USD 123.77 over the next 12 months. Blueprint Medicines Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Blueprint Medicines Corp is Neutral, which is based on 5 positive signals and 5 negative signals. At the last closing, Blueprint Medicines Corp’s stock price was USD 96.62. Blueprint Medicines Corp’s stock price has changed by -0.95% over the past week, +8.79% over the past month and +64.15% over the last year.
No recent analyst target price found for Blueprint Medicines Corp
No recent average analyst rating found for Blueprint Medicines Corp
Company Overview Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Read Less
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal st...Read More
Frequently Asked Questions About Blueprint Medicines Corp (BPMC) Stock
Based on ratings from 9 analysts Blueprint Medicines Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 8 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on BPMC's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for BPMC is USD 123.77 over the next 12 months. The maximum analyst target price is USD 140 while the minimum anlayst target price is USD 105.
BPMC stock's Price/Earning ratio is 19.36.
Our analysis grades BPMC stock's Price / Earning ratio at F. This means that BPMC stock's Price/Earning ratio is above 70% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BPMC may be a overvalued for its sector.
The last closing price of BPMC's stock was USD 96.62.
The most recent market capitalization for BPMC is USD 5.76B.
Based on targets from 9 analysts, the average taret price for BPMC is projected at USD 123.77 over the next 12 months.
This means that BPMC's stock price may go up by +28.10% over the next 12 months.
We can't find any ETFs which contains Blueprint Medicines Corp's stock.
As per our most recent records Blueprint Medicines Corp has 638 Employees.
Blueprint Medicines Corp's registered address is 45 Sidney Street, Cambridge, MA, United States, 02139.
You can get more information about it from Blueprint Medicines Corp's website at https://www.blueprintmedicines.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Blueprint Medicines Corp (BPMC) Stock
Based on ratings from 9 analysts Blueprint Medicines Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 8 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on BPMC's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for BPMC is USD 123.77 over the next 12 months. The maximum analyst target price is USD 140 while the minimum anlayst target price is USD 105.
BPMC stock's Price/Earning ratio is 19.36.
Our analysis grades BPMC stock's Price / Earning ratio at F. This means that BPMC stock's Price/Earning ratio is above 70% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BPMC may be a overvalued for its sector.
The last closing price of BPMC's stock was USD 96.62.
The most recent market capitalization for BPMC is USD 5.76B.
Based on targets from 9 analysts, the average taret price for BPMC is projected at USD 123.77 over the next 12 months.
This means that BPMC's stock price may go up by +28.10% over the next 12 months.
We can't find any ETFs which contains Blueprint Medicines Corp's stock.
As per our most recent records Blueprint Medicines Corp has 638 Employees.
Blueprint Medicines Corp's registered address is 45 Sidney Street, Cambridge, MA, United States, 02139.
You can get more information about it from Blueprint Medicines Corp's website at https://www.blueprintmedicines.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BPMC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
